Skip to main content
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. — Investor Relations & Filings

Ticker · XLO ISIN · US98422T1007 US Professional, scientific and technical activities
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US XLO

About Xilio Therapeutics, Inc.

https://xiliotx.com/

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology (IO) therapies for cancer treatment. The company utilizes a proprietary, clinically validated platform to engineer biologics, including antibodies, masked bispecifics, and T cell engagers. These molecules are designed to be 'masked' or inactive in systemic circulation and become fully active only within the tumor microenvironment. This approach aims to concentrate the therapeutic effect precisely on the tumor, thereby minimizing systemic toxicity and improving the efficacy-to-toxicity ratio of potent immunotherapies. Xilio's pipeline consists of multiple clinical and preclinical programs designed to deliver powerful cancer treatments to a broader patient population.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It contains detailed information about the upcoming Annual Meeting of Stockholders, including voting items such as election of directors, amendments to the certificate of incorporation, and ratification of the independent auditor. The document is titled 'Definitive Additional Materials' related to the proxy statement and includes instructions for voting and information about the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document length is 4082 characters, which is consistent with a detailed proxy statement or additional proxy materials. Therefore, the correct classification is PSI.
2025-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC for the 2025 Annual Meeting of Stockholders of Xilio Therapeutics, Inc. It includes detailed information about the solicitation of proxies, proposals to be voted on at the meeting (such as election of directors, amendments to the certificate of incorporation, and ratification of the independent auditor), corporate governance, executive compensation, and other matters typically included in proxy statements. The document explicitly identifies itself as a proxy statement and includes instructions for voting and attending the virtual meeting. It is not an annual report, earnings release, or other financial report, but rather a solicitation document for shareholder voting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is a full proxy statement, not a brief notice or announcement.
2025-04-18 English
Director's Dealing 2025
Director's Dealing
2025-04-16 English
Director's Dealing 2025
Director's Dealing
2025-04-16 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 4, 2025, by Xilio Therapeutics, Inc. The content focuses on a notice received from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. It details the deficiency notice, the compliance period, potential transfer to Nasdaq Capital Market, and possible delisting procedures. This is a formal announcement of a delisting risk and related compliance steps, not a financial report or earnings release. The document length is 5711 characters, which is sufficient for a substantive announcement. The key section is "Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing." This matches the definition of a Delisting Announcement (DLST). Therefore, the correct classification is DLST with high confidence.
2025-04-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.